These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32338703)

  • 1. FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019.
    Chen EY; Haslam A; Prasad V
    JAMA Intern Med; 2020 Jun; 180(6):912-914. PubMed ID: 32338703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. US Food and Drug Administration approves first cancer treatment for any solid tumors with specific biomarker.
    Cancer; 2017 Oct; 123(19):3652-3653. PubMed ID: 28940329
    [No Abstract]   [Full Text] [Related]  

  • 3. Cutting-edge cancer drug hobbled by diagnostic test confusion.
    Ledford H
    Nature; 2018 Apr; 556(7700):161-162. PubMed ID: 29636574
    [No Abstract]   [Full Text] [Related]  

  • 4. Approvals in 2018: a histology-agnostic new molecular entity, novel end points and real-time review.
    Blumenthal GM; Pazdur R
    Nat Rev Clin Oncol; 2019 Mar; 16(3):139-141. PubMed ID: 30670830
    [No Abstract]   [Full Text] [Related]  

  • 5. Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World.
    Mailankody S; Prasad V
    JAMA Oncol; 2017 Jul; 3(7):889-890. PubMed ID: 27892992
    [No Abstract]   [Full Text] [Related]  

  • 6. Interpretation of surrogate endpoints in the era of the 21st Century Cures Act.
    Knopf K; Baum M; Shimp WS; Bennett CL; Faith D; Fishman ML; Hrushesky WJ
    BMJ; 2016 Dec; 355():i6286. PubMed ID: 28039123
    [No Abstract]   [Full Text] [Related]  

  • 7. Assessing tumor-related signs and symptoms to support cancer drug approval.
    Williams G; Pazdur R; Temple R
    J Biopharm Stat; 2004 Feb; 14(1):5-21. PubMed ID: 15027497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate.
    Chen EY; Raghunathan V; Prasad V
    JAMA Intern Med; 2019 Jul; 179(7):915-921. PubMed ID: 31135822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials.
    Chen EY; Joshi SK; Tran A; Prasad V
    JAMA Intern Med; 2019 May; 179(5):642-647. PubMed ID: 30933235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA treads delicate line between safety and speed.
    Oncology (Williston Park); 1999 Jan; 13(1):16. PubMed ID: 10027195
    [No Abstract]   [Full Text] [Related]  

  • 12. Cancer drug approval in the United States, Europe, and Japan.
    Milsted RA
    Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686
    [No Abstract]   [Full Text] [Related]  

  • 13. Recasting cancer trials.
    Nat Biotechnol; 2012 Jul; 30(7):567. PubMed ID: 22781659
    [No Abstract]   [Full Text] [Related]  

  • 14. Cancer drugs approved for use in children: Impact of legislative initiatives and future opportunities.
    Barone A; Casey D; McKee AE; Reaman G
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27809. PubMed ID: 31144772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. End points and United States Food and Drug Administration approval of oncology drugs.
    Johnson JR; Williams G; Pazdur R
    J Clin Oncol; 2003 Apr; 21(7):1404-11. PubMed ID: 12663734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory watch: Why do oncology drugs fail to gain US regulatory approval?
    Khozin S; Liu K; Jarow JP; Pazdur R
    Nat Rev Drug Discov; 2015 Jul; 14(7):450-1. PubMed ID: 26000722
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of the fDA in cancer clinical trials.
    Hirschfeld S
    Cancer Treat Res; 2007; 132():51-109. PubMed ID: 17305017
    [No Abstract]   [Full Text] [Related]  

  • 18. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
    Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
    Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer drugs remain FDA approved despite lack of benefit, study finds.
    McCarthy M
    BMJ; 2016 Dec; 355():i6568. PubMed ID: 27923801
    [No Abstract]   [Full Text] [Related]  

  • 20. Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency.
    Maeda H; Kurokawa T
    Ann Oncol; 2015 Jan; 26(1):211-216. PubMed ID: 25361994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.